The Graft That Grows
Nationwide Children’s Hospital is home to the pioneering inventors of the tissue-engineered vascular graft (TEVG) a landmark advance with the potential to transform care for children undergoing the Fontan operation. Built on decades of innovation and advanced through Nationwide Children’s research and clinical leadership, these grafts form living, flexible blood vessels that grow with the child. Currently being evaluated in a clinical trial, the technology has received Breakthrough Device Designation from the U.S. Food and Drug Administration.
A New Approach to Advance Outcomes
TEVGs are bioresorbable scaffolds seeded with the patient’s own cells that support the body's ability to grow a new blood vessel that we call a neovessel. After six months to a year, the scaffold has completely resorbed, leaving only tissue that structurally and functionally resembles a native blood vessel.
Decades of research support our TEVG, showing that it outperforms standard of care conduits by resisting calcification and growing with the child, reducing the number of interventions over the patient's lifespan.
Designed for Better Flow
Compliant tissue optimizes laminar flow in the vessel, like a native blood vessel, helping protect the liver, kidneys and other organs.
Grows With the Child
The neovessels that result from the TEVG grow with the child, helping ensure the graft remains the right size over time.
Strong Preclinical Data Currently Under Clinical Investigation
Clinical trial and animal studies have demonstrated an outstanding safety profile.
Decades in the Making
The TEVG story spans more than 30 years of research, translation, collaboration and clinical development.
Beginning a Collaboration
Christopher Breuer, MD, and Toshiharu Shinoka, MD, PhD, meet at Harvard University and begin their tissue engineering work together.
First-in-Human U.S. Implant
Drs. Breuer and Shinoka implant the first vascular graft in a human in the United States as part of a landmark clinical trial.
Program Moves to Nationwide Children’s
After the first patient, Drs. Breuer and Shinoka move to Nationwide Children’s Hospital where they enroll 3 more patients in the first clinical trial.
First Clinical Trial Closes
The first clinical trial closed early because of graft narrowing. Those patients received additional treatment and are still doing well.
TEVG2 Clinical Trial Opens
The single arm clinical trial is evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
FDA Breakthrough Device Designation
The TEVG program receives Breakthrough Device Designation from the U.S. Food and Drug Administration.
Neovessel Biosciences Forms
Nationwide Children's launches Neovessel Biosciences, a startup company to advance the technology.
National Scientific Recognition
Dr. Breuer gives a plenary presentation about TEVG at the American Heart Association Annual Scientific Meeting.
Expanding Access
Ongoing work is focused on advancing the technology toward broader availability for children who may benefit.
Scroll horizontally to explore the timeline →
The People Behind the Progress
TEVG development has been shaped by clinical leadership, scientific partnership and a multidisciplinary team committed to advancing pediatric care.
Christopher Breuer, MD
Co Inventor of the TEVG
Director of the Center for Regenerative Medicine at Nationwide Children’s and chief scientific officer of Neovessel.
Meet Dr. Breuer
Mark Galantowicz, MD
Principal Investigator, TEVG Trial
Cardiothoracic surgeon, co director of The Heart Center at Nationwide Children’s and surgical director of Neovessel.
Meet Dr. Galantowicz
Toshiharu Shinoka, MD, PhD
Co Inventor of the TEVG
Dr. Shinoka leaves an enduring legacy in pediatric cardiac surgery, regenerative medicine and the countless lives he touched.
In Memoriam